Psoriasis Treatment: What’s in the Future?

Continued

The biologic agents approved by the FDA for treatment of moderate to severe psoriasis include:

Biologic agents work well for treating psoriasis: in clinical trials, each of the drugs reduced psoriasis activity by at least 75% in many people. However, these new medications have drawbacks. Biologic agents for psoriasis treatment can cost hundreds or thousands of dollars per month. Although safe for most people, close monitoring is needed for an increased risk of infection, cancer, and other complications.

Apremilast (Otezla)

Apremilast is an oral drug approved to treat psoriatic arthritis and plaque psoriasis in adults. It's an inhibitor of phosphodieasterase-4 (PDE-4), an enzyme that controls inflammation within a cell. Side effects include diarrhea, nausea, and headache. These side effects may stop with continued treatment. In studies, a small number of people stopped taking Apremilast because of an adverse reaction. Some participants also had unexplained weight loss. It's recommended that those taking the drug have their weight monitored regularly and also be monitored for depression.

WebMD Medical Reference Reviewed by Jennifer Robinson, MD on April 29, 2015

Sources

SOURCES:

Nickoloff, B.J., Journal of Clinical Investigation, 2004; vol 113: pp 1664-1675.

Lowes, M.A., Nature, 2007; vol 445: pp 866-873.

Callen, J.P., Journal of the American Academy of Dermatology, 2003; vol 49: pp 351-356.

Saini, R., Current Pharmaceutical Design, 2005; vol 11: pp 273-280.

Lebwohl, M., Journal of the American Academy of Dermatology, 2003; vol 49: pp S118-S124.

News release, FDA.

© 2015 WebMD, LLC. All rights reserved.

Pagination